Kohjin Bio Co., Ltd.
177A.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.16 | -0.48 | 0.17 | 0.00 |
| FCF Yield | 0.31% | 2.64% | -1.01% | 4.71% |
| EV / EBITDA | 5.82 | 11.08 | 7.28 | 10.86 |
| Quality | ||||
| ROIC | 9.37% | 6.13% | 16.26% | 13.65% |
| Gross Margin | 45.45% | 39.44% | 51.74% | 51.66% |
| Cash Conversion Ratio | 0.90 | 1.30 | 0.37 | 0.83 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.16% | 6.52% | 16,801,506.04% | 15,803,607.14% |
| Free Cash Flow Growth | -89.25% | 362.01% | -117.80% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -0.54 | 0.78 | 0.44 | 0.43 |
| Interest Coverage | 32.96 | 26.09 | 39.04 | 24.90 |
| Efficiency | ||||
| Inventory Turnover | 3.22 | 4.23 | 2.08 | 3.66 |
| Cash Conversion Cycle | 153.66 | 122.84 | 204.48 | 131.22 |